| Literature DB >> 27342193 |
Devarajan Rathish1, Sivaswamy Bahini2, Thanikai Sivakumar2, Thilani Thiranagama2, Tharmarajah Abarajithan3, Buddhika Wijerathne4, Channa Jayasumana2, Sisira Siribaddana5.
Abstract
BACKGROUND: Prescription writing is a process which transfers the therapeutic message from the prescriber to the patient through the pharmacist. Prescribing errors, drug duplication and potential drug-drug interactions (pDDI) in prescriptions lead to medication error. Assessment of the above was made in prescriptions dispensed at State Pharmaceutical Corporation (SPC), Anuradhapura, Sri Lanka.Entities:
Keywords: Drug interactions; Drug utilization; Prescription analysis; Prescription error; Sri Lanka
Mesh:
Substances:
Year: 2016 PMID: 27342193 PMCID: PMC4921016 DOI: 10.1186/s40360-016-0071-z
Source DB: PubMed Journal: BMC Pharmacol Toxicol ISSN: 2050-6511 Impact factor: 2.483
Top 10 drugs in prescriptions dispensed at SPC Anuradhapura 2015
| Total | Government | Private & Unclassified | |||
|---|---|---|---|---|---|
| Drug | % ( | Drug | % ( | Drug | % ( |
| Atorvastatin | 4.0 | Atorvastatin | 7.1 | Atorvastatin | 3.5 |
| Losartan | 3.8 | Losartan | 7.1 | Metformin | 3.5 |
| Metformin | 3.6 | Aspirin | 6.5 | Losartan | 3.3 |
| Pantoprazole | 2.9 | Metformin | 4.2 | Pantoprazole | 2.9 |
| Aspirin | 2.7 | Clopidogrel | 3.3 | Gliclazide | 2.5 |
| Gliclazide | 2.5 | Pantoprazole | 2.9 | Aspirin | 2.1 |
| Diclofenac sodium | 1.8 | Gliclazide | 2.7 | Diclofenac sodium | 1.9 |
| Celecoxib | 1.6 | Amlodipine | 2.5 | Celecoxib | 1.7 |
| Clopidogrel | 1.6 | Domperidone | 2.5 | Esomeprazole | 1.6 |
| Omeprazole | 1.6 | Omeprazole | 2.1 | Prednisolone | 1.6 |
Top 5 subgroups (n = 3668) in prescriptions dispensed at SPC Anuradhapura 2015
| ATC 4th level | Percent | ATC 3rd level | Percent | ATC 2nd level | Percent |
|---|---|---|---|---|---|
| Chemical subgroup | Pharmacological subgroup | Therapeutic subgroup | |||
| Proton pump inhibitor | 7.0 | Anti-inflammatory and anti-rheumatic products, non-steroids | 8.8 | Anti-inflammatory and anti-rheumatic products | 8.8 |
| HMG CoA reductase inhibitors | 5.0 | Blood glucose lowering drugs, excluding Insulins | 8.3 | Drugs used in diabetes | 8.4 |
| Angiotensin II antagonists, plain | 4.9 | Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | 7.6 | Drugs for acid related disorders | 7.9 |
| Platelet aggregation inhibitors excluding heparin | 4.3 | Lipid modifying agents, plain | 5.8 | Anti-bacterials for systemic use | 7.3 |
| Sulfonylureas | 3.6 | Angiotensin II antagonists, plain | 4.9 | Lipid modifying agents | 5.8 |
Combination products prescribed in prescriptions dispensed at SPC Anuradhapura 2015
| No | Groups of combined preparations | % ( |
|---|---|---|
| 01 | Vitamins | 36 |
| 02 | Anti-anemic preparations | 17 |
| 03 | Mineral supplements | 14 |
| 04 | Drugs for obstructive airway diseases | 11 |
| 05 | Analgesics | 09 |
| 06 | Corticosteroids, dermatological preparations | 04 |
| 07 | Anti-acne preparations | 04 |
| 08 | Drugs for acid related disorders | 02 |
| 09 | Vasoprotectives | 01 |
| 10 | Antifungals for dermatological use | 01 |
| 11 | Anti-Parkinson drugs | 01 |
Completeness of prescriptions (Total = 1000) dispensed at SPC Anuradhapura 2015
| Component of the prescription | Present (complete/correct) |
|---|---|
| Patient information | |
| 1. Name of patient | 94 (42c) |
| 2. Age of patient | 79 |
| 3. Gender of patient | 70 |
| 4. Address of patient | 5 |
| Prescriber information | |
| 5. Name of prescriber | 90 (98c) |
| 6. Signature of prescriber | 84 |
| 7. SLMC registration number | 35 |
| 8. Place of prescribing | 76 |
| 9. Contact details of prescriber | 53 |
| 10. Qualifications of the prescriber | 86 |
| 11. Prescriber's rubber stamp containing - Full name, qualifications, and registration number below his signature | 89 (36c) |
| Drug information | |
| 12. Route of administration | 7 (90b) |
| 13. Generic name of drug | 16 (87b) |
| 14. Dose of drug | 93 (33b) |
| 15. Frequency of drug | 97 (68b) |
| 16. Duration of drug | 92 (84b) |
| Other information | |
| 17. Treatment symbol | 48 (61b) |
| 18. Date of prescribing | 88 (94c) |
| 19. Diagnosis of the diseasea | 41 |
| 20. Refill informationa | 6 |
aItem 19 & 20 are in addition to the guidelines available in the BNF and WHO manual [3, 4]
bCorrect, cComplete
Errors in prescriptions dispensed at SPC Anuradhapura 2015
| Route | Generic name | Dose | Frequency | Duration | pDDIs | Drug class Duplication | SLMC Number | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ( | ( | ( | ( | ( | ( | ( | ( | |||||||||
| C | I | C | I | C | I | C | I | C | I | P | A | P | A | C | I | |
| Government | 11 | 144 | 52 | 103 | 71 | 84 | 105 | 50 | 120 | 35 | 82 | 47 | 25 | 104 | 28 | 127 |
| Private & | 52 | 793 | 93 | 752 | 233 | 612 | 558 | 287 | 649 | 196 | 384 | 374 | 105 | 653 | 320 | 525 |
|
| 0.070 | 51.883 | 19.73 | 0.103 | 0.004 | 6.856 | 2.269 | 21.778 | ||||||||
|
| 0.792 | 0.000 | 0.000 | 0.748 | 0.950 | 0.009 | 0.132 | 0.000 | ||||||||
C – Present, Correct or Complete; I – absent, Incorrect or Incomplete, P - Present; A - Absent
Common pDDIs of prescriptions dispensed at SPC Anuradhapura 2015
| Combination (%) | Mechanism of pDDI according to the Medscape drug interaction checker [ |
|---|---|
| Serious (Total = 94) | |
| Methotrexate-Leflunomide (6.4) | Leflunomide increases toxicity of methotrexate by pharmacodynamic synergism. |
| Meloxicam-Methotrexate (5.3) | Meloxicam increases levels of methotrexate by decreasing renal clearance. |
| Clopidogrel-Omeprazole (5.3) | Omeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. |
| Clopidogrel-Esomeprazole (5.3) | Esomeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. |
| Atorvastatin-Vitamin B3 (5.3) | Either increases toxicity of the other by pharmacodynamic synergism. |
| Atorvastatin-Fenofibrate (5.3) | Either increases effects of the other by pharmacodynamic synergism. |
| Significant (Total = 1017) | |
| Aspirin-Losartan (5.5) | Aspirin decreases effects of losartan by pharmacodynamic antagonism. losartan and aspirin both increase serum potassium. |
| Losartan-Frusemide (3.2) | Losartan increases and furosemide decreases serum potassium. |
| Aspirin-Clopidogrel (3.0) | Either increases toxicity of the other by pharmacodynamic synergism. |
| Clopidogrel-Pantoprazole (2.3) | Pantoprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. |
| Celecoxib-Diclofenac sodium (2.0) | Celecoxib and diclofenac both increase anticoagulation and serum potassium. |
| Aspirin-Frusemide (2.0) | Aspirin increases and furosemide decreases serum potassium. |
| Minor (Total = 265) | |
| Glipizide - Sitagliptin (7.6) | Either increases effects of the other by pharmacodynamic synergism. |
| Metformin - Vitamin B12 (5.7) | Metformin decreases levels of cyanocobalamin by unspecified interaction mechanism. |
| Metformin-Frusemide (3.8) | Metformin decreases levels of furosemide by unspecified interaction mechanism. Furosemide increases levels of metformin by unspecified interaction mechanism. |
| Methotrexate - Folic acid (3.4) | Folic acid decreases effects of methotrexate by pharmacodynamic antagonism. |
| Aspirin-Diltiazem (2.6) | Diltiazem increases effects of aspirin by unknown mechanism. |
| Metformin-Hydrochlorothiazide (2.6) | Hydrochlorothiazide will increase the level or effect of metformin by basic (cationic) drug competition for renal tubular clearance. Hydrochlorothiazide decreases effects of metformin by pharmacodynamic antagonism. |